Regardless of the initial enthusiasm following drug development, the use of the trastuzumab MAb in the treatment of ErbB2-expressing advanced GC frequently fails to ameliorate the overall survival of the majority of patients [55]. This evidence concerns the gene ERBB2 and gastric cancer.